Trials / Completed
CompletedNCT03486457
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB (CP-690,550) IN CHINESE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO AT LEAST ONE CONVENTIONAL SYNTHETIC DMARD
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib | tablets, 5 mg BID x 6 months |
| OTHER | Placebo | tablets, to match tofacitinib 5 mg BID x 3 months |
| DRUG | Tofacitinib | tablets, 5 mg BID x 3 months |
Timeline
- Start date
- 2018-08-10
- Primary completion
- 2021-04-28
- Completion
- 2021-04-28
- First posted
- 2018-04-03
- Last updated
- 2024-02-08
- Results posted
- 2024-02-08
Locations
38 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03486457. Inclusion in this directory is not an endorsement.